Literature DB >> 23801474

Evaluation of patency of arteriovenous fistula and its relative complications in diabetic patients.

Seyed Saeed Mortaz1, Ali Davati, Maryam Khan Ahmadloo, Hamid Reza Taheri, Farzaneh Golfam, Azin Tavakoli, Ali Reza Khalaj.   

Abstract

PURPOSE: To study the arteriovenous fistula patency, duration of its maintenance, and its relative complications.
MATERIALS AND METHODS: One hundred and thirty patients who had undergone hemodialysis during five years (1996 to 2001) were included in this study. The patency rate and complications, including paresthesia, pain induced by ischemia, venous hypertension, infection, erythema, and edema, were assessed. Data were recorded in the pre-designed questionnaire and statistically analyzed using t test.
RESULTS: Mean ± standard deviation age of the patients was 58.08 ± 11.73 years (range, 18 to 80 years). Most of the fistulas were created at the left bracheocephalic (58 subjects). Side-to-side technique was the mostly applied technique (99.2%). The fistula patency was 100%, 92.64%, 89.48%, 84.38%, and 83.61% at year 1 to 5, respectively. There was a significant negative correlation between the subjects' age and maintained patency (P = .02). However, no significant difference was observed between the maintained patency and other variables, including gender, location of the fistula, and the type of the technique applied for creation of the fistula (P > .05).
CONCLUSION: Diabetes does not have a negative impact on the rate of patency and its duration in arteriovenous fistula. However, further investigations on a larger population are recommended.

Entities:  

Mesh:

Year:  2013        PMID: 23801474

Source DB:  PubMed          Journal:  Urol J        ISSN: 1735-1308            Impact factor:   1.510


  1 in total

1.  Relationship of late arteriovenous fistula stenosis with soluble E-selectin and soluble EPCR in chronic hemodialysis patients with arteriovenous fistula.

Authors:  Mukadder Ayse Bilgic; Hakki Yilmaz; Alper Bozkurt; Huseyin Tugrul Celik; Ismail Celal Bilgic; Ozgul Malcok Gurel; Ismail Kirbas; Nuket Bavbek; Ali Akcay
Journal:  Clin Exp Nephrol       Date:  2014-03-14       Impact factor: 2.801

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.